HARROW INC (HROW) Stock Fundamental Analysis

USA • Nasdaq • NASDAQ:HROW • US4158581094

46.45 USD
-0.87 (-1.84%)
Last: Feb 9, 2026, 10:28 AM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

5

HROW gets a fundamental rating of 5 out of 10. The analysis compared the fundamentals against 191 industry peers in the Pharmaceuticals industry. Both the profitability and the financial health of HROW get a neutral evaluation. Nothing too spectacular is happening here. HROW shows excellent growth, but is valued quite expensive already.


Dividend Valuation Growth Profitability Health

6

1. Profitability

1.1 Basic Checks

  • In the past year HROW was profitable.
  • HROW had a positive operating cash flow in the past year.
  • In the past 5 years HROW always reported negative net income.
  • In multiple years HROW reported negative operating cash flow during the last 5 years.
HROW Yearly Net Income VS EBIT VS OCF VS FCFHROW Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50M -100M

1.2 Ratios

  • HROW has a better Return On Assets (-1.37%) than 74.87% of its industry peers.
  • HROW has a better Return On Equity (-10.60%) than 73.30% of its industry peers.
  • Looking at the Return On Invested Capital, with a value of 7.48%, HROW belongs to the top of the industry, outperforming 85.34% of the companies in the same industry.
  • The Average Return On Invested Capital over the past 3 years for HROW is significantly below the industry average of 12.65%.
  • The 3 year average ROIC (1.25%) for HROW is below the current ROIC(7.48%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA -1.37%
ROE -10.6%
ROIC 7.48%
ROA(3y)-7.09%
ROA(5y)-9.18%
ROE(3y)-36.88%
ROE(5y)-57.31%
ROIC(3y)1.25%
ROIC(5y)1.34%
HROW Yearly ROA, ROE, ROICHROW Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100 -200 -300 -400

1.3 Margins

  • The Operating Margin of HROW (11.27%) is better than 83.77% of its industry peers.
  • HROW's Operating Margin has improved in the last couple of years.
  • The Gross Margin of HROW (74.56%) is better than 81.15% of its industry peers.
  • In the last couple of years the Gross Margin of HROW has grown nicely.
Industry RankSector Rank
OM 11.27%
PM (TTM) N/A
GM 74.56%
OM growth 3Y20.78%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.21%
GM growth 5Y2.29%
HROW Yearly Profit, Operating, Gross MarginsHROW Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

4

2. Health

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), HROW is destroying value.
  • Compared to 1 year ago, HROW has more shares outstanding
  • Compared to 5 years ago, HROW has more shares outstanding
  • The debt/assets ratio for HROW has been reduced compared to a year ago.
HROW Yearly Shares OutstandingHROW Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M
HROW Yearly Total Debt VS Total AssetsHROW Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

  • An Altman-Z score of 4.01 indicates that HROW is not in any danger for bankruptcy at the moment.
  • The Altman-Z score of HROW (4.01) is better than 69.11% of its industry peers.
  • A Debt/Equity ratio of 5.17 is on the high side and indicates that HROW has dependencies on debt financing.
  • The Debt to Equity ratio of HROW (5.17) is worse than 81.68% of its industry peers.
Industry RankSector Rank
Debt/Equity 5.17
Debt/FCF N/A
Altman-Z 4.01
ROIC/WACC0.77
WACC9.73%
HROW Yearly LT Debt VS Equity VS FCFHROW Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M

2.3 Liquidity

  • HROW has a Current Ratio of 2.72. This indicates that HROW is financially healthy and has no problem in meeting its short term obligations.
  • HROW has a Current ratio (2.72) which is in line with its industry peers.
  • A Quick Ratio of 2.52 indicates that HROW has no problem at all paying its short term obligations.
  • HROW has a Quick ratio (2.52) which is in line with its industry peers.
Industry RankSector Rank
Current Ratio 2.72
Quick Ratio 2.52
HROW Yearly Current Assets VS Current LiabilitesHROW Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

8

3. Growth

3.1 Past

  • HROW shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 109.68%, which is quite impressive.
  • The Revenue has grown by 47.83% in the past year. This is a very strong growth!
  • The Revenue has been growing by 31.29% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)109.68%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%283.33%
Revenue 1Y (TTM)47.83%
Revenue growth 3Y40.17%
Revenue growth 5Y31.29%
Sales Q2Q%45.44%

3.2 Future

  • The Earnings Per Share is expected to grow by 72.94% on average over the next years. This is a very strong growth
  • Based on estimates for the next years, HROW will show a very strong growth in Revenue. The Revenue will grow by 39.09% on average per year.
EPS Next Y122.31%
EPS Next 2Y128.52%
EPS Next 3Y105.44%
EPS Next 5Y72.94%
Revenue Next Year39.67%
Revenue Next 2Y40.91%
Revenue Next 3Y39.47%
Revenue Next 5Y39.09%

3.3 Evolution

  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
HROW Yearly Revenue VS EstimatesHROW Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M 1B
HROW Yearly EPS VS EstimatesHROW Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 2 4 6

More info and screens

Find the best growth stocksShow best growing peers

3

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings ratio is 516.11, which means the current valuation is very expensive for HROW.
  • Based on the Price/Earnings ratio, HROW is valued a bit cheaper than the industry average as 74.87% of the companies are valued more expensively.
  • HROW's Price/Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 27.93.
  • The Price/Forward Earnings ratio is 32.76, which means the current valuation is very expensive for HROW.
  • HROW's Price/Forward Earnings ratio is a bit cheaper when compared to the industry. HROW is cheaper than 72.25% of the companies in the same industry.
  • The average S&P500 Price/Forward Earnings ratio is at 27.77. HROW is around the same levels.
Industry RankSector Rank
PE 516.11
Fwd PE 32.76
HROW Price Earnings VS Forward Price EarningsHROW Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 100 200 300 400 500

4.2 Price Multiples

  • HROW's Enterprise Value to EBITDA ratio is a bit cheaper when compared to the industry. HROW is cheaper than 78.53% of the companies in the same industry.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 41.01
HROW Per share dataHROW EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 6

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
  • The decent profitability rating of HROW may justify a higher PE ratio.
  • HROW's earnings are expected to grow with 105.44% in the coming years. This may justify a more expensive valuation.
PEG (NY)4.22
PEG (5Y)N/A
EPS Next 2Y128.52%
EPS Next 3Y105.44%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for HROW!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

HARROW INC

NASDAQ:HROW (2/9/2026, 10:28:07 AM)

46.45

-0.87 (-1.84%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-10
Earnings (Next)03-16
Inst Owners58.38%
Inst Owner Change0.58%
Ins Owners14.8%
Ins Owner Change2.47%
Market Cap1.72B
Revenue(TTM)250.04M
Net Income(TTM)-4.99M
Analysts85.71
Price Target72.13 (55.29%)
Short Float %17.78%
Short Ratio9.95
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)819.91%
Min EPS beat(2)-18.12%
Max EPS beat(2)1657.94%
EPS beat(4)2
Avg EPS beat(4)222.09%
Min EPS beat(4)-970.3%
Max EPS beat(4)1657.94%
EPS beat(8)3
Avg EPS beat(8)30%
EPS beat(12)4
Avg EPS beat(12)-52.89%
EPS beat(16)5
Avg EPS beat(16)-847.87%
Revenue beat(2)0
Avg Revenue beat(2)-5.01%
Min Revenue beat(2)-5.31%
Max Revenue beat(2)-4.71%
Revenue beat(4)1
Avg Revenue beat(4)-5.43%
Min Revenue beat(4)-17.73%
Max Revenue beat(4)6.04%
Revenue beat(8)2
Avg Revenue beat(8)-3.74%
Revenue beat(12)4
Avg Revenue beat(12)-3.32%
Revenue beat(16)7
Avg Revenue beat(16)-1.63%
PT rev (1m)0%
PT rev (3m)4.12%
EPS NQ rev (1m)-5.62%
EPS NQ rev (3m)-22.46%
EPS NY rev (1m)-6.43%
EPS NY rev (3m)-77.05%
Revenue NQ rev (1m)-0.25%
Revenue NQ rev (3m)-6.08%
Revenue NY rev (1m)-0.07%
Revenue NY rev (3m)-3.52%
Valuation
Industry RankSector Rank
PE 516.11
Fwd PE 32.76
P/S 6.88
P/FCF N/A
P/OCF 96.26
P/B 36.59
P/tB N/A
EV/EBITDA 41.01
EPS(TTM)0.09
EY0.19%
EPS(NY)1.42
Fwd EY3.05%
FCF(TTM)-0.56
FCFYN/A
OCF(TTM)0.48
OCFY1.04%
SpS6.75
BVpS1.27
TBVpS-3.43
PEG (NY)4.22
PEG (5Y)N/A
Graham Number1.6
Profitability
Industry RankSector Rank
ROA -1.37%
ROE -10.6%
ROCE 9.46%
ROIC 7.48%
ROICexc 9.96%
ROICexgc 45.18%
OM 11.27%
PM (TTM) N/A
GM 74.56%
FCFM N/A
ROA(3y)-7.09%
ROA(5y)-9.18%
ROE(3y)-36.88%
ROE(5y)-57.31%
ROIC(3y)1.25%
ROIC(5y)1.34%
ROICexc(3y)2.44%
ROICexc(5y)3.09%
ROICexgc(3y)9.66%
ROICexgc(5y)8.29%
ROCE(3y)1.58%
ROCE(5y)1.69%
ROICexgc growth 3Y16.24%
ROICexgc growth 5YN/A
ROICexc growth 3Y-9.77%
ROICexc growth 5YN/A
OM growth 3Y20.78%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.21%
GM growth 5Y2.29%
F-Score7
Asset Turnover0.69
Health
Industry RankSector Rank
Debt/Equity 5.17
Debt/FCF N/A
Debt/EBITDA 5.18
Cap/Depr 207.09%
Cap/Sales 15.46%
Interest Coverage 1.19
Cash Conversion 38.15%
Profit Quality N/A
Current Ratio 2.72
Quick Ratio 2.52
Altman-Z 4.01
F-Score7
WACC9.73%
ROIC/WACC0.77
Cap/Depr(3y)560.55%
Cap/Depr(5y)363.77%
Cap/Sales(3y)46.48%
Cap/Sales(5y)28.73%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)109.68%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%283.33%
EPS Next Y122.31%
EPS Next 2Y128.52%
EPS Next 3Y105.44%
EPS Next 5Y72.94%
Revenue 1Y (TTM)47.83%
Revenue growth 3Y40.17%
Revenue growth 5Y31.29%
Sales Q2Q%45.44%
Revenue Next Year39.67%
Revenue Next 2Y40.91%
Revenue Next 3Y39.47%
Revenue Next 5Y39.09%
EBIT growth 1Y428.64%
EBIT growth 3Y69.3%
EBIT growth 5YN/A
EBIT Next Year1305.78%
EBIT Next 3Y233.73%
EBIT Next 5Y132.11%
FCF growth 1Y87.15%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y308.55%
OCF growth 3YN/A
OCF growth 5YN/A

HARROW INC / HROW FAQ

Can you provide the ChartMill fundamental rating for HARROW INC?

ChartMill assigns a fundamental rating of 5 / 10 to HROW.


Can you provide the valuation status for HARROW INC?

ChartMill assigns a valuation rating of 3 / 10 to HARROW INC (HROW). This can be considered as Overvalued.


Can you provide the profitability details for HARROW INC?

HARROW INC (HROW) has a profitability rating of 6 / 10.


How financially healthy is HARROW INC?

The financial health rating of HARROW INC (HROW) is 4 / 10.


What is the expected EPS growth for HARROW INC (HROW) stock?

The Earnings per Share (EPS) of HARROW INC (HROW) is expected to grow by 122.31% in the next year.